SmartPeptide
Start Free
SleepLimited human evidence

DSIP

Delta sleep-inducing peptide originally isolated in studies of EEG slow-wave activity. Modern human data is sparse.

Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.

What the research shows

1970s–1980s studies described EEG slow-wave changes and effects on stress markers. Some small clinical reports in chronic insomnia and pain populations.

What's still experimental

Very little modern, well-controlled human research. Mechanisms remain only partially characterized.

Anecdotal / community reports

Sleep-quality reports vary wildly online; placebo effects are likely substantial.

Anecdotal reports are NOT scientific evidence. They reflect personal experience and may not generalize.

FDA approval status

Source: openFDA + DailyMed (NIH/NLM)
No FDA-approved drug label exists for “DSIP”. This peptide is not currently approved by the FDA as a finished pharmaceutical product. Any commercial product claiming FDA approval should be treated with suspicion.

Doses studied in research

No established dose range

What published trials tested or FDA-approved labels specify. Reporting research facts — not a SmartPeptide recommendation.

No FDA-approved or established trial dose range for this peptide. Anecdotal ranges discussed in community forums exist but are not supported by published clinical trials, and SmartPeptide will not publish unverified doses.

This is the honest answer for peptides like BPC-157, IGF-1 LR3, MOTS-c, Epitalon and similar research compounds — robust human dose- ranging studies have not been published. Always work with a licensed clinician familiar with experimental peptides if you are considering any use.

FDA enforcement & recalls

Live · openFDA Drug Enforcement API
Total actions
1
recalls + withdrawals
Ongoing
1
not yet completed
Class I (serious)
0
health hazard / death risk
  • Class IIOngoing· Voluntary: Firm initiated
    FDA record

    DSIP, 1000 MCG/ML, 5 ML vial, The Guyer Institute of Molecular Medicine, Indianapolis, IN

    Reason: Lack of Assurance of Sterility: due to concerns with production processes which cannot assure sterility of products intended to be sterile.

    Nov 30, 2020·Advanced Nutriceuticals, LLC
FDA classifications: Class I = reasonable probability of serious adverse health consequences or death. Class II = temporary or medically reversible adverse consequences. Class III = unlikely to cause adverse health consequences.

Mechanism & targets

ChEMBL · UniProt · Open Targets

Molecule (ChEMBL)

View on ChEMBL
Formula
C35H48N10O15

Protein targets (UniProt)

  • TSC22 domain family protein 3
    Q99576gene: TSC22D3Homo sapiens· 134 aaReviewed

    Protects T-cells from IL2 deprivation-induced apoptosis through the inhibition of FOXO3A transcriptional activity that leads to the down-regulation of the pro-apoptotic factor BCL2L11 (PubMed:15031210). In macrophages, plays a role in the anti-inflammatory and immunosuppressive effects of glucocorticoids and IL10 (PubMed:12393603). In T-cells, inhibits anti-CD3-induced NFKB1 nuclear translocation and thereby NFKB1 DNA-binding activities (PubMed:11468175). In vitro, suppresses AP-1 transcription…

  • TSC22 domain family protein 3
    P80220gene: TSC22D3Sus scrofa· 77 aaReviewed

    Protects T-cells from IL2 deprivation-induced apoptosis through the inhibition of FOXO3A transcriptional activity that leads to the down-regulation of the pro-apoptotic factor BCL2L11. In macrophages, plays a role in the anti-inflammatory and immunosuppressive effects of glucocorticoids and IL10. In T-cells, inhibits anti-CD3-induced NFKB1 nuclear translocation. In vitro, suppresses AP1 and NFKB1 DNA-binding activities. Inhibits myogenic differentiation and mediates anti-myogenic effects of gluc…

  • Delta sleep-inducing peptide
    P01158Oryctolagus cuniculus· 9 aaReviewed

    When infused into the mesodiencephalic ventricle of recipient rabbits induces spindle and delta EEG activity and reduced motor activities

Live research

PubMed · ClinicalTrials.gov · Europe PMC · OpenAlex
PubMed papers
0
total
Human studies
0
MeSH: humans
Clinical trials
0
published
Active trials
14
84 total registered

Clinical trials (ClinicalTrials.gov)

All trials for "delta sleep inducing peptide"

Europe PMC — 3,217 additional records

Includes EU/UK studies and PubMed Central full-text articles. Often surfaces research weeks before PubMed indexes it.

Research volume (OpenAlex topic graph)

Total works
12,617
all years
Last 5 years
5,983
recent activity
Open access
11,896
freely readable
OA share
94%
of all works

Human clinical evidence

Semantic Scholar · AI TLDRs · influence-ranked
Semantic Scholar API is currently rate-limited.

Human-study summaries for “delta sleep-inducing peptide” are available on Semantic Scholar but the shared free-tier API quota is exhausted right now. Try refreshing in a few minutes, or check the PubMed and Europe PMC panels above for the same literature.

Research funding & verification

NIH RePORTER · CrossRef DOI registry

NIH-funded research

U.S. National Institutes of Health
Funded projects
400
all years
Top award sum
$80.6M
aggregate USD
Years covered
16
research span
Largest active / recent grants

Publication landscape

CrossRef · DOI registry
Indexed works (CrossRef)
668,001
all DOIs registered
Retracted papers
0
no retractions on record
Top funders of indexed research
  • National Natural Science Foundation of China18,197 works
  • National Institutes of Health6,661 works
  • National Key Research and Development Program of China2,521 works
  • Japan Society for the Promotion of Science2,384 works
  • National Science Foundation2,059 works
  • National Research Foundation of Korea1,996 works

Funder diversity is a credibility signal. Research concentrated in a single drug company's funding warrants more scrutiny than research funded across NIH, charities, and academic grants.

Preprints — cutting edge

bioRxiv · medRxiv · via Europe PMC

Preprints have NOT been peer-reviewed. They are early research shared by authors before formal validation. Treat findings as preliminary.

Showing 6 of 15 preprints indexed by Europe PMC.

Known risks

Limited modern clinical data.

Reported side effects

Poorly characterized.

FDA adverse event reports (FAERS)

Updated quarterly by FDA
No reports found in the FDA Adverse Event Reporting System for “DSIP”. This is normal for research-only peptides that are not marketed as FDA-approved drugs.

What requires medical supervision

Limited modern safety data. Use only with clinician oversight.

Questions for your clinician

  • What modern (post-2010) clinical evidence exists?
  • How does DSIP compare with established sleep interventions?

Editorially curated references

Discussions about DSIP

Start a discussion
No discussions yet — be the first. Share what you've learned, what worked, what didn't, or a study you want translated into plain English.
See all DSIP discussions Native, moderated, no buying or selling